Global Arthritis Monoclonal Antibodies Markets 2022-2031: Focus on Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia
Global Arthritis Monoclonal Antibodies Market
Dublin, June 23, 2022 (GLOBE NEWSWIRE) -- The "Arthritis Monoclonal Antibodies Global Market Report 2022: By Drug, By Application, By End-Use" report has been added to ResearchAndMarkets.com's offering.
Arthritis Monoclonal Antibodies Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global arthritis monoclonal antibodies (mab's) market.
This report focuses on arthritis monoclonal antibodies (mab's) market which is experiencing strong growth. The report gives a guide to the arthritis monoclonal antibodies (mab's) market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider arthritis monoclonal antibodies (mab's) market, and compares it with other markets.
Where is the largest and fastest growing market for the arthritis monoclonal antibodies (mab's)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Arthritis Monoclonal Antibodies (mab's) market global report answers all these questions and many more.
The countries covered in the arthritis monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Report Scope
The market characteristics section of the report defines and explains the market
The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth
Market segmentations break down market into sub markets
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets
Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers
The arthritis monoclonal antibodies (mab's) market section of the report gives context. It compares the arthritis monoclonal antibodies (mab's) market with other segments of the arthritis monoclonal antibodies (mab's) market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, arthritis monoclonal antibodies (mab's) indicators comparison
Markets Covered:
By Drug: Remicade; Humira; Enbrel; Rituxan; Orencia; Actemra; Simponi; Cimzia; Remsima
By Application: Rheumatoid Arthritis; Osteoarthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Fibromyalgia; Others
By End-Use: Hopitals; Research Institutes; Others
Major Companies Mentioned:
Johnson & Johnson
Roche
Novartis
Pfizer Inc
AbbVie Inc
Key Topics Covered:
1. Executive Summary
2. Arthritis Monoclonal Antibodies Market Characteristics
3. Arthritis Monoclonal Antibodies Market Trends And Strategies
4. Impact Of COVID-19 On Arthritis Monoclonal Antibodies
5. Arthritis Monoclonal Antibodies Market Size And Growth
5.1. Global Arthritis Monoclonal Antibodies Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Arthritis Monoclonal Antibodies Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Arthritis Monoclonal Antibodies Market Segmentation
6.1. Global Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
Remicade
Humira
Enbrel
Rituxan
Orencia
Actemra
Simponi
Cimzia
Remsima
6.2. Global Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
Rheumatoid Arthritis
Osteoarthritis
Psoriatic Arthritis
Ankylosing Spondylitis
Fibromyalgia
Others
6.3. Global Arthritis Monoclonal Antibodies Market, Segmentation By End-use, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
Hopitals
Research Institutes
Others
7. Arthritis Monoclonal Antibodies Market Regional And Country Analysis
7.1. Global Arthritis Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Arthritis Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
Companies Mentioned
Johnson & Johnson
Roche
Novartis
Pfizer inc.
AbbVie inc.
Amgen inc.
Genentech
GSK
AstraZeneca plc.
Mylan N.V.
Bristol Myers Squibb
Eli Lily and Company
Thermofischer Scientific
Sanofi
Novo Nordisk A/S
Daiichi Sankyo Company ltd.
Seattle genetics
Teva pharmaceutical industries
Shanghi Junsi bioscience ltd.
GenScript
Sigma-Aldrich Co. LLC
AbGenomics
ADC Therapeutics
Agensys
Alexion Pharmaceuticals
ALMAC Group
Ambrx
Astellas Pharma
Celgene
Celldex Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/edvcu2
Attachment
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900